Sixfold Bioscience
Sixfold Bio is revolutionizing RNA therapies by addressing the critical challenge of RNA delivery. Their platform, inspired by nature and powered by AI, utilizes a proprietary programmable RNA tag called Mergo®. Mergo® encodes RNA modifications to influence delivery destination, enabling targeted delivery of RNA to cell types beyond the liver, which currently remains untargetable for most RNA therapeutics. The company leverages a combination of machine learning for Mergo design, innovative chemistry and automation for rapid production, and high-throughput testing for optimization. This approach dramatically reduces the time and cost of data acquisition in developing new RNA delivery systems. Their solution is poised to unlock the full potential of RNA medicine by expanding therapeutic targeting.
Sixfold Bioscience
Sixfold Bio is revolutionizing RNA therapies by addressing the critical challenge of RNA delivery. Their platform, inspired by nature and powered by AI, utilizes a proprietary programmable RNA tag called Mergo®. Mergo® encodes RNA modifications to influence delivery destination, enabling targeted delivery of RNA to cell types beyond the liver, which currently remains untargetable for most RNA therapeutics. The company leverages a combination of machine learning for Mergo design, innovative chemistry and automation for rapid production, and high-throughput testing for optimization. This approach dramatically reduces the time and cost of data acquisition in developing new RNA delivery systems. Their solution is poised to unlock the full potential of RNA medicine by expanding therapeutic targeting.